Clinical trials: Leishmaniasis, Visceral
Leishmaniasis, Visceral
Evaluation of Antibody Detection Tests for Visceral Leishmaniasis Diagnosis in Eastern Africa
According to recent estimates by the World Health Organization (WHO) on eastern Africa, not all visceral leishmaniasis (VL) cases reported are confirmed by a laboratory test, probably due to limited access to accurate diagnostic…
- Trial name
- VL-DX-EAFR (NCT03646981)
- Testing
- Leishmania Ab Rapid Test (CTK, Biotech)
- Where
- 2 sites in Ethiopia, Kenya
- Volunteers
- 704 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Brucelloses, Epidemic Hemorrhagic Fever
Real World Study of Classic Infectious Disease
This study aimed to collect and analyze clinical specimens of patients with classic infectious diseases in the real world. To investigate the epidemiological distribution of classic infectious diseases (brucellosis, epidemic…
- Conditions
- Brucelloses, Epidemic Hemorrhagic Fever, Kala-Azar
- Trial name
- NCT04020536
- Testing
- Antibiotics
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Huashan Hospital
Visceral Leishmaniasis
Improved Case Detection and Vector Control for Visceral Leishmaniasis
Visceral leishmaniasis (VL) also known as kala-azar is a public health problem in Bangladesh. Since 2005 a national kala-azar elimination program is going on in the country.
- Trial name
- NCT03269006
- Testing
- Inesfly Paint, IDWL (1m), ITN (KO-Tab 123)
- Where
- Bangladesh
- Volunteers
- 202 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Visceral Leishmaniasis
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition
The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of Astellas Pharma US, Inc., in patients…
- Trial name
- NCT03636659
- Testing
- Amphotericin B Liposome, AmBisome (Amphotericin B) Liposome
- Where
- 3 sites in Bangladesh, India
- Volunteers
- 140 people
- Sponsor
- Aurobindo Pharma Ltd
Post Kala Azar Dermal Leishmaniasis
Miltefosine for Children With PKDL
Hypothesis: Primary hypothesis: 1. Oral treatment with Miltefosine in children with PKDL at allometric daily dose (based on body weight and height) for 12 weeks is safe with a cure rate of ≥95%. Secondary hypothesis: 2.
- Trial name
- NCT02193022
- Testing
- Miltefosine
- Where
- Bangladesh
- Volunteers
- 80 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Visceral Leishmaniasis
Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.
The overall objective of this trial is to identify a safe and effective treatment for visceral leishmaniasis (VL) in HIV co-infected Ethiopian patients.
- Trial name
- NCT02011958
- Testing
- Liposomal Amphotericin B, Miltefosine
- Where
- 2 sites in Ethiopia
- Volunteers
- 59 people
- Sponsor
- Drugs for Neglected Diseases
Visceral Leishmaniosis, HIV-infection/Aids
Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Visceral leishmaniosis (VL) is widely reported in Ethiopia, with about 30% of cases being associated with human immunodeficiency virus (HIV).
- Trial name
- NCT01360762
- Testing
- Pentamidine
- Where
- 3 sites in Ethiopia
- Volunteers
- 74 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Visceral Leishmaniasis
Asymptomatic Leishmania Infection in HIV Patients
To collect pilot data on the prevalence and incidence of asymptomatic Leishmania donovani infection in HIV infected individuals in a visceral leishmaniasis (VL)-HIV endemic region to inform the feasibility of a larger study…
- Trial name
- NCT02839603
- Where
- Ethiopia
- Volunteers
- 540 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Visceral Leishmaniasis
A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh
Kala azar (KA) or visceral leishmaniasis (VL) is endemic in several districts of Bangladesh with the highest incidence in Mymensingh, Pabna and Tangail districts.
- Trial name
- NCT01240473
- Testing
- Randomized trial for treatment of kala azar in Bangladesh
- Where
- Bangladesh
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Post-kala-azar Dermal Leishmaniasis
Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh
The safety and effectiveness of AmBisome 15 mg/kg, given over 15 days in 5 biweekly infusions of 3 mg/kg on an outpatient basis, is evaluated in clinically diagnosed PKDL patients of 12 years and older in a highly endemic area in…
- Trial name
- NCT03311607
- Testing
- AmBisome
- Volunteers
- 280 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Leishmaniasis, Visceral
A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.
Sitamaquine is an 8-aminoquinoline which is being developed as an oral treatment for visceral leishmaniasis (VL). Pre-clinical and subsequent clinical investigations have demonstrated oral efficacy against Leishmania donovani.
- Trial name
- NCT00381394
- Testing
- sitamaquine
- Where
- 3 sites in India
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Visceral Leishmaniasis
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
The purpose of this study is to determine if amphotericin B is effective against visceral leishmaniasis in Brazilian children. Amphotericin B will be compared to meglumine antimoniate which is the current approved drug used for…
- Trial name
- LVTO (NCT01032187)
- Testing
- Meglumine antimoniate, Amphotericin B-deoxycholate
- Where
- 2 sites in Brazil
- Volunteers
- 101 people
- Sponsor
- University of Brasilia
Visceral Leishmaniasis
Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
This study is aimed to compare the efficacy and safety of medications currently used in Brazil for treatment of visceral leishmaniasis.
- Trial name
- LVBrasil (NCT01310738)
- Testing
- Antimoniate of N-methylglucamine, amphotericin B deoxycholate, Liposomal amphotericin B
- Where
- 5 sites in Brazil
- Volunteers
- 378 people
- Sponsor
- University of Brasilia
Cost-effective and Sustainable Vector Control Methods Will be Established to Reduce VL in India, Bangladesh and Nepal
Replacement of Insecticides to Control Visceral Leishmaniasis (VL)
Visceral leishmaniasis (VL) is a public health problem in Bangladesh, India and Nepal. To control the disease in these three countries a National kala-azar elimination program is ongoing.
- Trial name
- NCT01644682
- Testing
- IWFPL, IDWL, ITN
- Where
- Bangladesh
- Volunteers
- 3,600 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Visceral Leishmaniasis
Immunogenetics of Visceral Leishmaniasis
Visceral leishmaniasis is a potentially fatal disease caused in South America by the protozoan Leishmania chagasi. In neighborhoods with high exposure rates, the outcome of human infection with L.
- Trial name
- NCT00342823
- Where
- Brazil
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Primary Visceral Leishmaniasis
Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa
This study is to assess if shorter combinations of SSG plus single dose AmBisome®, Miltefosine plus single dose AmBisome® and Miltefosine alone are effective in treating visceral leishmaniasis in Eastern Africa.
- Trial name
- NCT01067443
- Testing
- Liposomal amphotericin B (AmBisome®) and sodium stibogluconate, Liposomal amphotericin B + miltefosine, Miltefosine
- Where
- 3 sites in Kenya, Sudan
- Volunteers
- 151 people
- Sponsor
- Drugs for Neglected Diseases
Visceral Leishmaniasis, Human African Trypanosomiasis
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
Tropical fevers have been a diagnostic challenge from the antiquity. Nowadays, despite the availability of good diagnostic capacities, undifferentiated febrile illnesses continue to be a thorny problem for travel physicians.
- Conditions
- Visceral Leishmaniasis, Human African Trypanosomiasis, Enteric Fever, Melioidosis
- Trial name
- NCT01766830
- Testing
- rk28 ICT, IT LEISH (rK39), Immunochromatographic HAT test
- Where
- 7 sites in Cambodia, Democratic Republic of the Congo and 2 more
- Volunteers
- 1,927 people
- Sponsor
- University Hospital, Geneva
Visceral Leishmaniasis
Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa
This is a multicenter, non-comparative, open-label clinical trial to assess the Pharmacokinetics (PK) and safety of miltefosine using an allometric dose algorithm in the treatment of children with primary Visceral Leishmaniasis…
- Trial name
- NCT02431143
- Testing
- Miltefosine
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 30 people
- Sponsor
- Drugs for Neglected Diseases
Kala Azar
Miltefosine for Brazilian Visceral Leishmaniasis
Miltefosine will be administered to Brazilian patients with kala azar
- Trial name
- NCT00378495
- Testing
- Miltefosine: initially 2.5 mg/kg/day for 28 days
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- AB Foundation
Visceral Leishmaniasis
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
The purpose of this study is to assess the efficacy and safety of SSG 30 days alone, PM 21 days alone and SSG and PM as a combination course of 17 days in the treatment of patients with VL.
- Trial name
- NCT00255567
- Testing
- Sodium Stibogluconate, Paromomycin sulphate, SSG and Paromomycin sulphate
- Where
- 5 sites in Ethiopia, Kenya and 2 more
- Volunteers
- 1,142 people
- Sponsor
- Drugs for Neglected Diseases